Dissecting tumor responsiveness to immunotherapy: the experience of peptide-based melanoma vaccines

Burnet, 1970, The concept of immunological surveillance, Prog. Exp. Tumor Res., 13, 1, 10.1159/000386035 Dunn, 2002, Cancer immunoediting: from immunosurveillance to tumor escape, Nat. Immunol., 3, 991, 10.1038/ni1102-991 Houbiers, 1995, Antibodies against p53 are associated with poor prognosis of colorectal cancer, Br. J. Cancer, 72, 637, 10.1038/bjc.1995.386 Rosenberg, 1996, Development of cancer immunotherapies based on identification of the genes encoding cancer regression antigens, J. Natl. Cancer Inst., 88, 1635, 10.1093/jnci/88.22.1635 Boon, 1996, Human tumor antigens recognized by T lymphocytes, J. Exp. Med., 183, 725, 10.1084/jem.183.3.725 Anichini, 1999, An expanded peripheral T cell population to a cytotoxic T lymphocyte (CTL)-defined, melanocyte-specific antigen in metastatic melanoma patients impacts on generation of peptide-specific CTLs but does not overcome tumor escape from immune surveillance in metastatic lesions, J. Exp. Med., 190, 651, 10.1084/jem.190.5.651 Mukherji, 1990, T-cell clones that react against autologous human tumors, Immunol. Rev., 116, 33, 10.1111/j.1600-065X.1990.tb00803.x Weiss, 1999, Viruses, cancer and AIDS, FEMS Immunol. Med. Microbiol., 26, 227, 10.1111/j.1574-695X.1999.tb01393.x Penn, 2000, Post-transplant malignancy: the role of immunosuppression, Drug Safety, 23, 101, 10.2165/00002018-200023020-00002 Rosenberg, 1998, Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma, Nat. Med., 4, 321, 10.1038/nm0398-321 Nestle, 1998, Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells, Nat. Med., 4, 328, 10.1038/nm0398-328 Kugler, 2000, Regression of human metastatic renal cell carcinoma after vaccination with tumor cell–dendritic cell hybrids, Nat. Med., 6, 332, 10.1038/73193 Atkins, 1999, High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993, J. Clin. Oncol., 17, 2105, 10.1200/JCO.1999.17.7.2105 Fisher, 2000, Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma, Cancer J. Sci. Am., 6, S55 Marchand, 1999, Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1, Int. J. Cancer, 80, 219, 10.1002/(SICI)1097-0215(19990118)80:2<219::AID-IJC10>3.0.CO;2-S Hsueh, 1999, Active specific immunotherapy with polyvalent melanoma cell vaccine for patients with in-transit melanoma metastases, Cancer, 85, 2160, 10.1002/(SICI)1097-0142(19990515)85:10<2160::AID-CNCR10>3.0.CO;2-0 Dudley, 2002, Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes, Science, 298, 850, 10.1126/science.1076514 Marincola, 2000, Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance, Adv. Immunol., 74, 181, 10.1016/S0065-2776(08)60911-6 Theobald, 1998, The sequence alteration associated with a mutational hotspot in p53 protects cells from lysis by cytotoxic T lymphocytes specific for a flanking peptide epitope, J. Exp. Med., 188, 1017, 10.1084/jem.188.6.1017 Mocellin, 2001, Cytokines and immune response in the tumor microenvironment, J. Immunother., 24, 392, 10.1097/00002371-200109000-00002 Walker, 1997, Role of Fas ligand (CD95L) in immune escape: the tumor cell strikes back, J. Immunol., 158, 4521, 10.4049/jimmunol.158.10.4521 Chappell, 1999, Human melanoma cells do not express Fas (Apo-1/CD95) ligand, Cancer Res., 59, 59 Rosenberg, 2001, Progress in human tumour immunology and immunotherapy, Nature, 411, 380, 10.1038/35077246 Mandruzzato, 1997, A CASP-8 mutation recognized by cytolytic T lymphocytes on a human head and neck carcinoma, J. Exp. Med., 186, 785, 10.1084/jem.186.5.785 Renkvist, 2001, A listing of human tumor antigens recognized by T cells, Cancer Immunol. Immunother., 50, 3, 10.1007/s002620000169 Parmiani, 2002, Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going?, J. Natl. Cancer Inst., 94, 805, 10.1093/jnci/94.11.805 Cormier, 1997, Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A, Cancer J. Sci. Am., 3, 37 Lee, 1999, Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression, J. Immunol., 163, 6292, 10.4049/jimmunol.163.11.6292 Thurner, 1999, Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma, J. Exp. Med., 190, 1669, 10.1084/jem.190.11.1669 Wang, 1999, Phase I trial of a MART-1 peptide vaccine with incomplete Freund's adjuvant for resected high-risk melanoma, Clin. Cancer Res., 5, 2756 Panelli, 2000, Phase 1 study in patients with metastatic melanoma of immunization with dendritic cells presenting epitopes derived from the melanoma-associated antigens MART-1 and gp100, J. Immunother., 23, 487, 10.1097/00002371-200007000-00013 Scheibenbogen, 2000, Phase 2 trial of vaccination with tyrosinase peptides and granulocyte-macrophage colony-stimulating factor in patients with metastatic melanoma, J. Immunother., 23, 275, 10.1097/00002371-200003000-00012 Banchereau, 2001, Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine, Cancer Res., 61, 6451 Lee, 2001, Effects of interleukin-12 on the immune response to a multipeptide vaccine for resected metastatic melanoma, J. Clin. Oncol., 19, 3836, 10.1200/JCO.2001.19.18.3836 Pittet, 2001, Expansion and functional maturation of human tumor antigen-specific CD8+ T cells after vaccination with antigenic peptide, Clin. Cancer Res., 7, 796s Slingluff, 2001, Phase I trial of a melanoma vaccine with gp100(280–288) peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomes, Clin. Cancer Res., 7, 3012 Yamshchikov, 2001, Evaluation of peptide vaccine immunogenicity in draining lymph nodes and peripheral blood of melanoma patients, Int. J. Cancer, 92, 703, 10.1002/1097-0215(20010601)92:5<703::AID-IJC1250>3.0.CO;2-5 Coulie, 2002, Cytolytic T-cell responses of cancer patients vaccinated with a MAGE antigen, Immunol. Rev., 188, 33, 10.1034/j.1600-065X.2002.18804.x Schuler-Thurner, 2002, Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells, J. Exp. Med., 195, 1279, 10.1084/jem.20012100 Weber, 2003, Granulocyte-macrophage colony-stimulating factor added to a multipeptide vaccine for resected Stage II melanoma, Cancer, 97, 186, 10.1002/cncr.11045 Whiteside, 2003, Enzyme-linked immunospot, cytokine flow cytometry, and tetramers in the detection of T-cell responses to a dendritic cell-based multipeptide vaccine in patients with melanoma, Clin. Cancer Res., 9, 641 Rosenberg, 1998, Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens, J. Natl. Cancer Inst., 90, 1894, 10.1093/jnci/90.24.1894 Marshall, 2000, Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses, J. Clin. Oncol., 18, 3964, 10.1200/JCO.2000.18.23.3964 Machiels, 2002, Peptide-based cancer vaccines, Semin. Oncol., 29, 494, 10.1053/sonc.2002.35244 Pardoll, 1998, The role of CD4+ T cell responses in antitumor immunity, Curr. Opin. Immunol., 10, 588, 10.1016/S0952-7915(98)80228-8 Wang, 2001, The role of MHC class II-restricted tumor antigens and CD4+ T cells in antitumor immunity, Trends Immunol., 22, 269, 10.1016/S1471-4906(01)01896-8 Toes, 1999, CD4 T cells and their role in antitumor immune responses, J. Exp. Med., 189, 753, 10.1084/jem.189.5.753 Hersey, 1994, Expression of the co-stimulatory molecule B7 on melanoma cells, Int. J. Cancer, 58, 527, 10.1002/ijc.2910580413 Bakker, 1995, Generation of antimelanoma cytotoxic T lymphocytes from healthy donors after presentation of melanoma-associated antigen-derived epitopes by dendritic cells in vitro, Cancer Res., 55, 5330 Abdel-Wahab, 1998, Human dendritic cells, pulsed with either melanoma tumor cell lysates or the gp100 peptide (280–288), induce pairs of T-cell cultures with similar phenotype and lytic activity, Cell. Immunol., 186, 63, 10.1006/cimm.1998.1298 Altman, 1996, Phenotypic analysis of antigen-specific T lymphocytes, Science, 274, 94, 10.1126/science.274.5284.94 Nielsen, 2000, Status of activation of circulating vaccine-elicited CD8+ T cells, J. Immunol., 165, 2287, 10.4049/jimmunol.165.4.2287 Spagnoli, 2002, Cytotoxic T-cell induction in metastatic melanoma patients undergoing recombinant vaccinia virus-based immuno-gene therapy, Recent Results Cancer Res., 160, 195, 10.1007/978-3-642-59410-6_23 Yee, 1999, Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramers, J. Immunol., 162, 2227, 10.4049/jimmunol.162.4.2227 Yang, 1998, Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity, J. Clin. Oncol., 16, 197, 10.1200/JCO.1998.16.1.197 Lee, 1999, Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients, Nat. Med., 5, 677, 10.1038/9525 Monsurro, 2002, Functional heterogeneity of vaccine-induced CD8(+) T cells, J. Immunol., 168, 5933, 10.4049/jimmunol.168.11.5933 van der Bruggen, 1991, A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma, Science, 254, 1643, 10.1126/science.1840703 Marincola, 1996, Differential anti-MART-1/MelanA CTL activity in peripheral blood of HLA-A2 melanoma patients in comparison to healthy donors: evidence of in vivo priming by tumor cells, J. Immunother. Emphas. Immunol., 19, 266, 10.1097/00002371-199607000-00003 Pittet, 1999, High frequencies of naive Melan-A/MART-1-specific CD8(+) T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals, J. Exp. Med., 190, 705, 10.1084/jem.190.5.705 Coulie, 1992, Precursor frequency analysis of human cytolytic T lymphocytes directed against autologous melanoma cells, Int. J. Cancer, 50, 289, 10.1002/ijc.2910500220 D'Souza, 1998, Circulating Melan-A/Mart-1 specific cytolytic T lymphocyte precursors in HLA-A2+ melanoma patients have a memory phenotype, Int. J. Cancer, 78, 699, 10.1002/(SICI)1097-0215(19981209)78:6<699::AID-IJC6>3.0.CO;2-U Letsch, 2000, High frequencies of circulating melanoma-reactive CD8+ T cells in patients with advanced melanoma, Int. J. Cancer, 87, 659, 10.1002/1097-0215(20000901)87:5<659::AID-IJC7>3.0.CO;2-7 Lengauer, 1998, Genetic instabilities in human cancers, Nature, 396, 643, 10.1038/25292 Jager, 1997, Immunoselection in vivo: independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma, Int. J. Cancer, 71, 142, 10.1002/(SICI)1097-0215(19970410)71:2<142::AID-IJC3>3.0.CO;2-0 Ferrone, 1995, Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance, Immunol. Today, 16, 487, 10.1016/0167-5699(95)80033-6 Cormier, 1998, Heterogeneous expression of melanoma-associated antigens and HLA-A2 in metastatic melanoma in vivo, Int. J. Cancer, 75, 517, 10.1002/(SICI)1097-0215(19980209)75:4<517::AID-IJC5>3.0.CO;2-W Scheibenbogen, 1996, Expression of gp100 in melanoma metastases resected before or after treatment with IFN alpha and IL-2, J. Immunother. Emphas. Immunol., 19, 375, 10.1097/00002371-199609000-00007 Riker, 1999, Immune selection after antigen-specific immunotherapy of melanoma, Surgery, 126, 112, 10.1016/S0039-6060(99)70143-1 Wang, 2000, A natural history of melanoma: serial gene expression analysis, Immunol. Today, 21, 619, 10.1016/S0167-5699(00)01724-2 Wang, 2000, High-fidelity mRNA amplification for gene profiling, Nat. Biotechnol., 18, 457, 10.1038/74546 Wang, 2002, Prospective molecular profiling of melanoma metastases suggests classifiers of immune responsiveness, Cancer Res., 62, 3581 Panelli, 2002, Gene-expression profiling of the response of peripheral blood mononuclear cells and melanoma metastases to systemic IL-2 administration, Genome Biol., 3, 10.1186/gb-2002-3-7-research0035 Brown, 1999, Exploring the new world of the genome with DNA microarrays, Nat. Genet., 21, 33, 10.1038/4462 Wolfel, 1989, Lysis of human melanoma cells by autologous cytolytic T cell clones. Identification of human histocompatibility leukocyte antigen A2 as a restriction element for three different antigens, J. Exp. Med., 170, 797, 10.1084/jem.170.3.797 Pockaj, 1994, Localization of 111 indium-labeled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy. Augmentation with cyclophosphamide and correlation with response, Cancer, 73, 1731, 10.1002/1097-0142(19940315)73:6<1731::AID-CNCR2820730630>3.0.CO;2-H Dubey, 2003, Quantitative imaging of the T cell antitumor response by positron-emission tomography, Proc. Natl. Acad. Sci. U. S. A., 100, 1232, 10.1073/pnas.0337418100 Sallusto, 1999, Two subsets of memory T lymphocytes with distinct homing potentials and effector functions, Nature, 401, 708, 10.1038/44385 Lee, 1998, Functional dissociation between local and systemic immune response during anti-melanoma peptide vaccination, J. Immunol., 161, 4183 Panelli, 2000, A tumor-infiltrating lymphocyte from a melanoma metastasis with decreased expression of melanoma differentiation antigens recognizes MAGE-12, J. Immunol., 164, 4382, 10.4049/jimmunol.164.8.4382 Yee, 2001, In vivo tracking of tumor-specific T cells, Curr. Opin. Immunol., 13, 141, 10.1016/S0952-7915(00)00196-5 Jager, 2000, Clonal expansion of Melan A-specific cytotoxic T lymphocytes in a melanoma patient responding to continued immunization with melanoma-associated peptides, Int. J. Cancer, 86, 538, 10.1002/(SICI)1097-0215(20000515)86:4<538::AID-IJC16>3.0.CO;2-G Panelli, 2000, Expansion of tumor-T cell pairs from fine needle aspirates of melanoma metastases, J. Immunol., 164, 495, 10.4049/jimmunol.164.1.495 Kammula, 1999, Functional analysis of antigen-specific T lymphocytes by serial measurement of gene expression in peripheral blood mononuclear cells and tumor specimens, J. Immunol., 163, 6867 Ohnmacht, 2001, Short-term kinetics of tumor antigen expression in response to vaccination, J. Immunol., 167, 1809, 10.4049/jimmunol.167.3.1809 Page, 1999, Proteomic definition of normal human luminal and myoepithelial breast cells purified from reduction mammoplasties, Proc. Natl. Acad. Sci. U. S. A., 96, 12589, 10.1073/pnas.96.22.12589 Paweletz, 2001, Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front, Oncogene, 20, 1981, 10.1038/sj.onc.1204265 Rosenberg, 1988, Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report, N. Engl. J. Med., 319, 1676, 10.1056/NEJM198812223192527 Mocellin, 2001, Kinetics of cytokine expression in melanoma metastases classifies immune responsiveness, Int. J. Cancer, 93, 236, 10.1002/ijc.1328 Mocellin, 2003, Quantitative real time PCR: a powerful ally in cancer research, Trends Mol. Med., 9, 189, 10.1016/S1471-4914(03)00047-9 Tian, 1991, A polyadenylate binding protein localized to the granules of cytolytic lymphocytes induces DNA fragmentation in target cells, Cell, 67, 629, 10.1016/0092-8674(91)90536-8 Anderson, 1995, TIA-1: structural and functional studies on a new class of cytolytic effector molecule, Curr. Top. Microbiol. Immunol., 198, 131 Akdis, 2001, Mechanisms of interleukin-10-mediated immune suppression, Immunology, 103, 131, 10.1046/j.1365-2567.2001.01235.x Moore, 2001, Interleukin-10 and the interleukin-10 receptor, Annu. Rev. Immunol., 9, 683, 10.1146/annurev.immunol.19.1.683 Berman, 1996, Systemic administration of cellular IL-10 induces an effective, specific, and long-lived immune response against established tumors in mice, J. Immunol., 157, 231 Salazar-Onfray, 1995, IL-10 converts mouse lymphoma cells to a CTL-resistant, NK-sensitive phenotype with low but peptide-inducible MHC class I expression, J. Immunol., 154, 6291 Giovarelli, 1995, Local release of IL-10 by transfected mouse mammary adenocarcinoma cells does not suppress but enhances antitumor reaction and elicits a strong cytotoxic lymphocyte and antibody-dependent immune memory, J. Immunol., 155, 3112 Kundu, 1996, Antimetastatic and antitumor activities of interleukin 10 in a murine model of breast cancer, J. Natl. Cancer Inst., 88, 536, 10.1093/jnci/88.8.536 Huang, 1996, Interleukin 10 suppresses tumor growth and metastasis of human melanoma cells: potential inhibition of angiogenesis, Clin. Cancer Res., 2, 1969 Adris, 1999, IL-10 expression by CT26 colon carcinoma cells inhibits their malignant phenotype and induces a T cell-mediated tumor rejection in the context of a systemic Th2 response, Gene Ther., 6, 1705, 10.1038/sj.gt.3301012 Mocellin, 2003, The dual role of IL-10, Trends Immunol., 24, 36, 10.1016/S1471-4906(02)00009-1 Matzinger, 1994, Tolerance, danger, and the extended family, Annu. Rev. Immunol., 12, 991, 10.1146/annurev.iy.12.040194.005015 Smyth, 2001, A fresh look at tumor immunosurveillance and immunotherapy, Nat. Immunol., 2, 293, 10.1038/86297 Kelly, 2002, Induction of tumor-specific T cell memory by NK cell-mediated tumor rejection, Nat. Immunol., 3, 83, 10.1038/ni746 Agarwala, 2001, Histamine dihydrochloride: inhibiting oxidants and synergising IL-2-mediated immune activation in the tumour microenvironment, Expert Opin. Biol. Ther., 1, 869, 10.1517/14712598.1.5.869 Dokka, 2001, Interleukin-10-mediated inhibition of free radical generation in macrophages, Am. J. Physiol., Lung Cell. Mol. Physiol., 280, L1196, 10.1152/ajplung.2001.280.6.L1196 Bogdan, 1991, Macrophage deactivation by interleukin 10, J. Exp. Med., 174, 1549, 10.1084/jem.174.6.1549 Hellstrand, 2000, Histamine: a novel approach to cancer immunotherapy, Cancer Investig., 18, 347, 10.3109/07357900009012178 Agarwala, 2002, Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma, J. Clin. Oncol., 20, 125, 10.1200/JCO.20.1.125